Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP (Q28389577)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP	scientific article

Statements

scholarly article

0 references

Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP (English)

0 references

1 reference

based on heuristic

inferred from title

author name string

Xuan Jin

1

0 references

Huirong Ding

2

0 references

Ning Ding

3

0 references

Zhiying Fu

4

0 references

Yuqin Song

5

0 references

Jun Zhu

6

0 references

language of work or name

0 references

publication date

16 August 2012

0 references

Journal of Hematology & Oncology

0 references

5

0 references

1

0 references

51

0 references

https://scigraph.springernature.com/pub.10.1186/1756-8722-5-51

0 references

Digitoxin and its analogs as novel cancer therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3467177

20 March 2017

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3467177

20 March 2017

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3467177

20 March 2017

Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3467177

20 March 2017

The relationship between third-codon position nucleotide content, codon bias, mRNA secondary structure and gene expression in the drosophilid alcohol dehydrogenase genes Adh and Adhr

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3467177

20 March 2017

Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3467177

20 March 2017

The four types of Tregs in malignant lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3467177

29 September 2017

High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3467177

29 September 2017

Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3467177

29 September 2017

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3467177

29 September 2017

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3467177

29 September 2017

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3467177

29 September 2017

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3467177

29 September 2017

Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3467177

29 September 2017

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3467177

29 September 2017

Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3467177

29 September 2017

Complement activation determines the therapeutic activity of rituximab in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3467177

2 June 2018

Localisation of the C1q binding site within C1q receptor/calreticulin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3467177

2 June 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1186%2F1756-8722-5-51

21 January 2018

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

1 reference

https://api.crossref.org/works/10.1186%2F1756-8722-5-51

21 January 2018

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction

1 reference

https://api.crossref.org/works/10.1186%2F1756-8722-5-51

21 January 2018

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents

1 reference

https://api.crossref.org/works/10.1186%2F1756-8722-5-51

21 January 2018

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3467177

27 November 2018

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/22897949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22897949

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1756-8722-5-51

0 references

Dimensions Publication ID

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/1756-8722-5-51

0 references

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28389577&oldid=2042009727"